Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Water is a solvent and diluent for parenteral administration; it provides hydration and maintains osmotic balance. It has no pharmacological activity.
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
As a diluent for reconstitution of medications,As a vehicle for intravenous administration of compatible drug additives,For hydration in patients requiring fluid replacement
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
Intravenous administration; dose determined by clinical requirements for hydration, drug dilution, or vehicle for parenteral medications. Typical adult maintenance: 30 m L/kg/day, adjusted for electrolyte and fluid status.
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
Approximately 30-45 minutes; rapid redistribution due to constant renal clearance; clinically, water half-life is not typically measured since it is a vehicle
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
Water is not metabolized; it is distributed throughout body fluids and excreted primarily by the kidneys.
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Renal: >99% as free water; biliary/fecal: negligible
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
0% (water does not bind to plasma proteins)
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
0.55-0.7 L/kg (total body water); clinically, water distributes throughout total body water
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
Intravenous: 100%; subcutaneous: ~100% (complete absorption); intramuscular: ~100%
Intravenous: 100% (only route of administration).
No specific GFR-based dose adjustment; monitor fluid balance and avoid fluid overload in renal impairment. In oliguric or anuric patients (GFR <10 m L/min), reduce volume to match insensible losses plus urine output.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
No specific Child-Pugh based modification; use with caution in ascites or edema due to risk of fluid overload.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
Weight-based: Neonates and infants: 60-100 m L/kg/day for maintenance; adjust for dehydration or ongoing losses. Administer via intravenous route.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
Use lower end of dosing range due to decreased renal function and comorbidities; monitor for fluid overload and electrolyte disturbances. Typical starting dose: 20-30 m L/kg/day intravenously.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
None.
None.
Use only if solution is clear and container is intact,Do not use for intravenous injections that require isotonic solutions unless additives are used to achieve isotonicity,Risk of hemolysis if administered as a large volume hypotonic solution,Monitor for fluid overload in patients with renal impairment or cardiac disease
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Known hypersensitivity to any component,Use as a large volume intravenous infusion without appropriate additives to achieve isotonicity
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
No known food interactions. Patients on a sodium-restricted diet should be aware that this product contains no sodium.
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
Sterile Water for Injection is a parenteral fluid devoid of pharmacologic activity. There is no known teratogenic risk across all trimesters; water is an essential nutrient with no expected fetal harm when administered appropriately.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
Compatible with breastfeeding; water distributes into breast milk without known adverse effects. No M/P ratio applicable as it is a non-medicinal vehicle.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
No dose adjustment needed; water clearance and distribution remain unchanged in pregnancy.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
Sterile water for injection is not intended for direct intravenous administration; it is used for reconstitution of medications or as a diluent. If given intravenously without proper tonicity adjustments, it can cause hemolysis, hyponatremia, and cerebral edema.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
This product is used to mix with other medications before they are given as an injection or infusion.,Do not inject this water directly into a vein as it can cause serious side effects.,Tell your healthcare provider if you have any allergies or if you are on a sodium-restricted diet.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STERILE WATER FOR INJECTION IN PLASTIC CONTAINER vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, answered by our medical review team.
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER is a Irrigation Solution that works by Water is a solvent and diluent for parenteral administration; it provides hydration and maintains osmotic balance. It has no pharmacological activity.. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STERILE WATER FOR INJECTION IN PLASTIC CONTAINER and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STERILE WATER FOR INJECTION IN PLASTIC CONTAINER is: Intravenous administration; dose determined by clinical requirements for hydration, drug dilution, or vehicle for parenteral medications. Typical adult maintenance: 30 m L/kg/day, adjusted for electrolyte and fluid status.. The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STERILE WATER FOR INJECTION IN PLASTIC CONTAINER and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STERILE WATER FOR INJECTION IN PLASTIC CONTAINER is classified as Category C. Sterile Water for Injection is a parenteral fluid devoid of pharmacologic activity. There is no known teratogenic risk across all trimesters; water is an essential nutrient with no. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.